TearLab Corp fka TEAR

[ash111]

Good earnings, Interesting C.C ahead:

First Quarter 2017 Operational Highlights:

Expanded the U.S. active device base to approximately 4,500 TearLab Osmolarity Systems
Staffed 97% of U.S. field sales positions

Reduced operating expenses by 29% and operating loss by 46% compared to first quarter 2016

Reduced cash burn to $2.4 million, from $6.6 million in first quarter 2016

Achieved initial CE Marking for next generation platform, providing regulatory clearance in the European Union and European Free Trade Association member countries
Received regulatory approval for the TearLab Osmolarity System in Brazil, well ahead of anticipated schedule

most important.cash balance of $13.0 million as of March 31, 2017.

“In addition, we are very pleased that nearly all of our U.S. field sales positions were filled, and we have seen the positive impact of having a full sales team with a stronger start to our second quarter in both revenue and placements than what we experienced in early Q1 2017.”

http://globenewswire.com/news-release/2017/05/15/985090/0/en/TearLab-Corporation-Reports-First-Quarter-2017-Financial-Results.html